GLP-1 Market
LLY $1145.46 ▼ -1.0% NVO $37.49 ▼ -1.1% PFE $28.29 ▼ -0.8% VKTX $31.28 ▼ -4.0% KLRA $10.77 ▼ -5.7% GPCR $30.27 ▼ -3.2% RHHBY $51.91 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Phase 3

VK2735

VK2735

Company
Viking Therapeutics
Mechanism
dual GLP-1/GIP
Route
Oral & injectable
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Next milestone: VANQUISH-2 Phase 3 data (2026-Q3, estimated)

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 1, 2026

Find a Clinical Trial Near Me

See recruiting studies for VK2735 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07838740

    A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities

    Not yet reported Viking Therapeutics, Inc. 270 participants Est. completion 2027-07 2 sites Stand-alone
    Other conditions: Obese Adults
    View official trial listing →
  • Completed NCT NCT05203237

    Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

    Not yet reported Viking Therapeutics, Inc. 92 participants Est. completion 2024-12-03 1 site Stand-alone
    MASH Other conditions: Weight Loss
    View official trial listing →
  • Completed NCT NCT06068946

    VK2735 for Weight Management Phase 2

    Not yet reported Viking Therapeutics, Inc. 176 participants Est. completion 2024-04-02 20 sites Stand-alone
    Other conditions: Weight Loss
    View official trial listing →
  • Completed NCT NCT06828055

    VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

    Not yet reported Viking Therapeutics, Inc. 280 participants Est. completion 2025-08-15 15 sites Stand-alone
    Other conditions: Weight Loss
    View official trial listing →
  • Active, not recruiting NCT NCT07104383

    VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

    Not yet reported Viking Therapeutics, Inc. 1100 participants Est. completion 2027-08-01 127 sites Stand-alone
    Other conditions: Weight Loss
    View official trial listing →
  • Active, not recruiting NCT NCT07104500

    VK2735 for Weight Management Phase 3

    Not yet reported Viking Therapeutics, Inc. 4500 participants Est. completion 2027-08-01 137 sites Stand-alone
    Other conditions: Weight Loss
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

The Weekly Dose & livestreams

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.